Abstract
Background Despite major therapeutic advances, heart failure remains a life-threatening disorder, with 26 million patients worldwide, causing more deaths than cancer as a non-communicable disease. Therefore, novel strategies for the treatment of heart failure continue to be an important clinical need. Based on preclinical studies, allogenic human-induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) patches have been proposed as a potential therapeutic candidate for heart failure. We report the implantation of allogeneic hiPSC-CM patches in a patient with ischemic cardiomyopathy (ClinicalTrials.gov, #jRCT2053190081).
Methods The patches were produced under clinical-grade conditions and displayed cardiogenic phenotypes and safety in vivo (severe immunodeficient mice) without any genetic mutations in cancer-related genes. The patches were then implanted via thoracotomy into the left ventricle epicardium of the patient under immunosuppressive agents.
Results Positron emission tomography and computed tomography confirmed the possible efficacy and did not detect tumorigenesis in either the heart or other organs; the clinical symptoms improved 6 months after surgery, without any major adverse events, suggesting that the patches were well-tolerated. Furthermore, changes in the wall motion in the transplanted site were recovered, suggesting a favorable prognosis and the potential tolerance to exercise.
Conclusions This study is the first report of a successful transplant of hiPSC-CMs for severe ischemic cardiomyopathy.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Trial ID: jRCT2053190081
Funding Statement
This study was funded by Japan Agency for Medical Research and Development (AMED) under the Grant Numbers JP20bm0204003, JP17bk0104044, 19bk0104002, and JP20bk0104110.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The regenerative treatment protocol (Japan Registry of Clinical Trials, https://jrct.niph.go.jp/en-latest-detail/jRCT2053190081) using allogeneic iPSC-CM patches was approved by the institutional review boards of Osaka University (#199006-A) and the Ministry of Health, Labor, and Welfare, Japan (#2019-143).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Subject codes: Cell Therapy, Stem Cells, Translational Studies, Heart Failure, Myocardial Infarction
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Non-standard Abbreviations and Acronyms
- 4DCT
- four-dimensional computed tomography
- CGH
- comparative genomic hybridization
- CiRA
- Center for iPS Cell Research and Application, Kyoto University
- CNV
- copy number variation
- Cx
- circumflex coronary artery
- cTNT
- cardiac Troponin T
- ESS
- end-systolic wall stress
- FDG-PET
- fluorodeoxyglucose-positron emission tomography
- FWHM
- full-width at half-maximum
- HBSS(+)
- Hanks’ Balanced Salt Solution
- H&E
- hematoxylin and eosin
- hiPSC-CM
- human induced pluripotent stem cell-derived cardiomyocyte
- IABP
- intra-aortic balloon pumping
- LAD
- left anterior descending coronary artery
- LV
- left ventricle
- LVESVI
- left ventricle end-systolic volume index
- MBF
- myocardial blood flow
- MCB
- master cell bank
- MI
- myocardial infarction
- NOG
- NOD/Shi-scid, IL-2R γnull
- NYHA
- New York Heart Association classification
- PCI
- percutaneous coronary intervention
- peak VO2
- peak oxygen uptake
- PET
- positron emission tomography
- RCA
- right coronary artery
